582 related articles for article (PubMed ID: 31362788)
21. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
[TBL] [Abstract][Full Text] [Related]
22. Targeted treatment for sonic hedgehog-dependent medulloblastoma.
Kieran MW
Neuro Oncol; 2014 Aug; 16(8):1037-47. PubMed ID: 24951114
[TBL] [Abstract][Full Text] [Related]
23. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.
Collier NJ; Ali FR; Lear JT
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236
[TBL] [Abstract][Full Text] [Related]
24. Sonidegib for the treatment of advanced basal cell carcinoma.
Ramelyte E; Amann VC; Dummer R
Expert Opin Pharmacother; 2016 Oct; 17(14):1963-8. PubMed ID: 27538055
[TBL] [Abstract][Full Text] [Related]
25. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
[TBL] [Abstract][Full Text] [Related]
26. Safety and Tolerability of Sonic Hedgehog Pathway Inhibitors in Cancer.
Carpenter RL; Ray H
Drug Saf; 2019 Feb; 42(2):263-279. PubMed ID: 30649745
[TBL] [Abstract][Full Text] [Related]
27. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
Hwang D; Dismuke T; Tikunov A; Rosen EP; Kagel JR; Ramsey JD; Lim C; Zamboni W; Kabanov AV; Gershon TR; Sokolsky-Papkov PhD M
Nanomedicine; 2021 Feb; 32():102345. PubMed ID: 33259959
[TBL] [Abstract][Full Text] [Related]
28. The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma.
Lospinoso Severini L; Ghirga F; Bufalieri F; Quaglio D; Infante P; Di Marcotullio L
Expert Opin Ther Targets; 2020 Nov; 24(11):1159-1181. PubMed ID: 32990091
[TBL] [Abstract][Full Text] [Related]
29. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
Li QR; Zhao H; Zhang XS; Lang H; Yu K
Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
[TBL] [Abstract][Full Text] [Related]
30. Prostaglandin E1 Inhibits
Wu F; Zhang C; Zhao C; Wu H; Teng Z; Jiang T; Wang Y
Cancer Res; 2020 Jul; 80(13):2818-2832. PubMed ID: 32371475
[TBL] [Abstract][Full Text] [Related]
31. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature.
Campione E; Di Prete M; Lozzi F; Lanna C; Spallone G; Mazzeo M; Cosio T; Rapanotti C; Dika E; Gaziano R; Orlandi A; Bianchi L
Chemotherapy; 2020; 65(1-2):2-10. PubMed ID: 32777789
[TBL] [Abstract][Full Text] [Related]
32. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
De Smaele E; Ferretti E; Gulino A
Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
[TBL] [Abstract][Full Text] [Related]
33. Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib.
Cabezas-Camarero S; García-Barberán V; Pérez-Alfayate R; Gómez Del Pulgar ME; Cabrera-Martin MN; Casado-Fariñas I; Pérez-Segura P
Oncologist; 2024 May; 29(5):377-383. PubMed ID: 38438322
[TBL] [Abstract][Full Text] [Related]
34. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
[TBL] [Abstract][Full Text] [Related]
35. Identification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma.
Wei SF; He DH; Zhang SB; Lu Y; Ye X; Fan XZ; Wang H; Wang Q; Liu YQ
Biochem Pharmacol; 2021 Aug; 190():114593. PubMed ID: 33964282
[TBL] [Abstract][Full Text] [Related]
36. Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases.
Climans SA; Macdonald DR; Sutherland DE; Mason WP
BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33122230
[TBL] [Abstract][Full Text] [Related]
37. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.
Dummer R; Ascierto PA; Basset-Seguin N; Dréno B; Garbe C; Gutzmer R; Hauschild A; Krattinger R; Lear JT; Malvehy J; Schadendorf D; Grob JJ
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):1944-1956. PubMed ID: 31990414
[TBL] [Abstract][Full Text] [Related]
38. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
39. Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
Catenacci DV; Junttila MR; Karrison T; Bahary N; Horiba MN; Nattam SR; Marsh R; Wallace J; Kozloff M; Rajdev L; Cohen D; Wade J; Sleckman B; Lenz HJ; Stiff P; Kumar P; Xu P; Henderson L; Takebe N; Salgia R; Wang X; Stadler WM; de Sauvage FJ; Kindler HL
J Clin Oncol; 2015 Dec; 33(36):4284-92. PubMed ID: 26527777
[TBL] [Abstract][Full Text] [Related]
40. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
